Saturday 17 October 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.
22.07
0.55
−2.43%
Follow ANRO
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
10.29 | — | — | — | — |
P/Operating CF |
(6.70) | — | — | — | — |
P/B ratio |
0.00 | — | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | — |
EV/Operating CF |
(0.14) | — | — | — | — |
EV/FCF |
(0.13) | — | — | — | — |
Quick Ratio |
15.03 | 8.75 | 14.71 | 16.81 | 15.58 |
Current Ratio |
15.30 | 8.85 | 15.22 | 16.92 | 15.69 |
Net Debt/EBITDA |
2.16 | 1.35 | 1.94 | 2.30 | 2.40 |
Debt/Assets |
0.00% | 18.61% | 11.38% | 6.51% | 10.28% |
Debt/Equity |
0.00 | 0.28 | 0.14 | 0.08 | 0.13 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.01 | 0.74 | 0.92 | 0.77 | 0.82 |
Capex/Depreciation |
(4.69) | (2.14) | (1.26) | (4.13) | (0.04) |
Interest Coverage |
— | — | (27.60) | (49.90) | (26.88) |
| 0.00% | 108.91% | 65.96% | (153.99%) | (41.80%) | |
| 0.00% | (69.58%) | (52.81%) | (46.51%) | (34.92%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(34.11%) | (61.81%) | (44.88%) | (37.92%) | (37.58%) |
Average Days of Receivables |
2,598.45 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
3,985.71% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,855.24% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
108.10% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.89 | — | — | — | — |
Graham Number |
0.00 | — | — | — | — |
Earnings Yield |
(47.01%) | — | — | — | — |
Free Cash Flow Yield |
(43.92%) | — | — | — | — |
Revenue per Share |
0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(3.84) | (5.92) | (8.96) | (1.93) | (1.79) |
Capex per Share |
(0.28) | (0.21) | (0.13) | (0.08) | 0.00 |
Free Cash Flow per Share |
(4.12) | (6.13) | (9.09) | (2.01) | (1.80) |
Cash per Share |
10.65 | 14.03 | 22.12 | 6.84 | 6.12 |
Shareholders Equity per Share |
10.64 | 9.82 | 18.71 | 6.16 | 5.24 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.64 | 9.82 | 18.71 | 6.16 | 5.24 |
Free Cash Flow |
(9.94) | (21.13) | (33.92) | (49.50) | (51.79) |
Working Capital |
25.87 | 43.66 | 79.78 | 159.33 | 166.39 |
Capital Expenditures |
(0.68) | (0.73) | (0.47) | (2.07) | (0.02) |
Net Current Asset Value |
24.58 | 32.20 | 68.57 | 143.26 | 144.17 |
EV/EBIT |
0.00 | — | — | — | — |
Capex to Sales |
3.24 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — | — | — |
| Other line items | |||||
Depreciation/Fixed assets |
0.14 | 0.29 | 0.34 | 0.19 | 0.35 |
Cash ROIC |
(19.35%) | (23.05%) | (20.91%) | (14.94%) | (14.94%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.91 | 0.17 | — | — |
Average Payables |
— | 1.10 | 1.34 | 1.33 | 1.73 |
Average Assets |
— | 39.82 | 68.74 | 132.09 | 181.12 |
Average Common Equity |
— | (25.44) | (55.04) | 39.89 | 151.30 |
Columns are period end dates